ZMB Member Sebastian Bauer
ZMB Member
Sebastian Bauer
Next ZMB-Member
Prof. Dr. Sebastian Bauer
West German Cancer Center (WTZ)
University Hospital Essen
Hufelandstr. 55
45147 Essen
- +49 201 723 2112
- Website
- Selected Publications
- Publication Metrics
- ZMB Research Program
Oncology
Research Overview
- Analysis of oncogenetic signalling pathways in soft-tissue sarcoma (esp. GIST)
- Evaluation of purposive, small molecular inhibitors of tyrosine kinases in soft-tissue sarcoma
- Development of soft-tissue sarcoma models (cell lines and Xenografts)
- Evaluation of preclinical diagnostic techniques/methods (in vitro/in vivo) for GIST and other soft-tissue sarcoma
Selected Publications
-
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRAIn: Nature Communications Vol. 15 (2024) Nr. 1, 63Online Full Text: dx.doi.org/ (Open Access)
-
Correction to: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Vol. 15 (2024) Nr. 1, 2364Online Full Text: dx.doi.org/ (Open Access)
-
Ripretinib versus sunitinib in gastrointestinal stromal tumor : ctDNA biomarker analysis of the phase 3 INTRIGUE trialIn: Nature Medicine (2024) in pressOnline Full Text: dx.doi.org/ (Open Access)
-
Circulating tumor DNA analysis of the phase III VOYAGER trial : KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenibIn: Annals of Oncology Vol. 34 (2023) Nr. 7, pp. 615 - 625Online Full Text: dx.doi.org/
-
KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized TrialIn: Clinical Cancer Research Vol. 29 (2023) Nr. 17, pp. 3313 - 3319Online Full Text: dx.doi.org/ (Open Access)
-
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationIn: Nature Communications Vol. 14 (2023) Nr. 1, pp. 4632Online Full Text: dx.doi.org/ (Open Access)
-
Zoledronic Acid Add-on Therapy for Standard-Risk Ewing Sarcoma Patients in the Ewing 2008R1 TrialIn: Clinical Cancer Research Vol. 29 (2023) Nr. 24, pp. 5057 - 5068Online Full Text: dx.doi.org/
-
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations : Results from a Multi-institutional European Retrospective StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 8, pp. 1672 - 1679Online Full Text: dx.doi.org/ (Open Access)
-
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma : Results from a Proof-of-Concept, Phase Ib StudyIn: Clinical Cancer Research Vol. 28 (2022) Nr. 6, pp. 1087 - 1097Online Full Text: dx.doi.org/ (Open Access)
-
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersIn: Annals of Oncology Vol. 33 (2022) Nr. 11, pp. 1186 - 1199Online Full Text: dx.doi.org/ (Open Access)
-
Gastrointestinal stromal tumours : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 33 (2022) Nr. 1, pp. 20 - 33Online Full Text: dx.doi.org/ (Open Access)
-
Prognostic Factors for Leiomyosarcoma with Isolated Metastases to the Lungs : Impact of MetastasectomyIn: Annals of Surgical Oncology Vol. 29 (2022) Nr. 7, pp. 4429 - 4436Online Full Text: dx.doi.org/ (Open Access)
-
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaIn: Clinical Cancer Research Vol. 28 (2022) Nr. 5, pp. 870 - 881Online Full Text: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353Online Full Text: dx.doi.org/ (Open Access)
-
Bone sarcomas : ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 32 (2021) Nr. 12, pp. 1520 - 1536Online Full Text: dx.doi.org/ (Open Access)
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS StudyIn: Clinical Cancer Research Vol. 27 (2021) Nr. 23, pp. 6333 - 6342Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersIn: Cancer Discovery Vol. 11 (2021) Nr. 11, pp. 2780 - 2795Online Full Text: dx.doi.org/ (Open Access)
-
Resistance to avapritinib in pdgfra-driven gist is caused by secondary mutations in the pdgfra kinase domainIn: Cancer Discovery Vol. 11 (2021) Nr. 1, pp. 108 - 125Online Full Text: dx.doi.org/ (Open Access)
-
Soft tissue and visceral sarcomas : ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆In: Annals of Oncology Vol. 32 (2021) Nr. 11, 1348-1365Online Full Text: dx.doi.org/ (Open Access)
-
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR) : A multicentre, open-label, phase 1 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 935 - 946Online Full Text: dx.doi.org/
-
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS) : a double-blind, randomised, placebo-controlled, phase 3 trialIn: The Lancet Oncology Vol. 21 (2020) Nr. 7, pp. 923 - 934Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-upIn: JAMA Oncology Vol. 6 (2020) Nr. 8, pp. 1241 - 1246Online Full Text: dx.doi.org/ (Open Access)
-
Defective homologous recombination DNA repair as therapeutic target in advanced chordomaIn: Nature Communications Vol. 10 (2019) Nr. 1, pp. 1635Online Full Text: dx.doi.org/ (Open Access)
-
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN) : a randomised phase 3 trialIn: Lancet Vol. 394 (2019) Nr. 10197, pp. 478 - 487Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3 : European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'In: Annals of Oncology Vol. 29 (2018) Nr. 3, pp. 758 - 765Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv79 - iv95Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinibIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii584Online Full Text: dx.doi.org/ (Open Access)
-
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv68 - iv78Online Full Text: dx.doi.org/ (Open Access)
-
Health-related quality of life (HR-QoL) in elderly soft tissue sarcoma (STS) patients from the randomized phase II EPAZ study comparing pazopanib (PAZ) and doxorubicin (DOX) in first lineIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii577Online Full Text: dx.doi.org/ (Open Access)
-
Integrative genomic and transcriptomic analysis of leiomyosarcomaIn: Nature Communications Vol. 9 (2018) Nr. 1, pp. 144Online Full Text: dx.doi.org/ (Open Access)
-
Soft tissue and visceral sarcomas : ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upIn: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 4, pp. iv51 - iv67Online Full Text: dx.doi.org/ (Open Access)
-
Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical AdvancesIn: Annals of Oncology Vol. 29 (2018) Nr. 10, pp. 2037 - 2045Online Full Text: dx.doi.org/ (Open Access)
-
VOYAGER : An open-label, randomised, phase III study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)In: Annals of Oncology Vol. 29 (2018) Nr. Suppl. 8, pp. viii595Online Full Text: dx.doi.org/ (Open Access)
-
A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumorsIn: Annals of Oncology Vol. 28 (2017) Nr. 3, pp. 541 - 546Online Full Text: dx.doi.org/ (Open Access)
-
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations : European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'In: Annals of Oncology Vol. 28 (2017) Nr. 12, pp. 3000 - 3008Online Full Text: dx.doi.org/
-
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trialIn: JAMA Oncology Vol. 3 (2017) Nr. 5, pp. 602 - 609Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferationIn: Nature Communications Vol. 8 (2017) pp. 14674Online Full Text: dx.doi.org/ (Open Access)
-
Sustained mutant KIT activation in the Golgi complex is mediated by PKC-θ in gastrointestinal stromal tumorsIn: Clinical Cancer Research Vol. 23 (2017) Nr. 3, pp. 845 - 856Online Full Text: dx.doi.org/
-
1401PD - Subgroup analysis of leiomyosarcoma (LMS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced liposarcoma (LPS) and LMSIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. vi485Online Full Text: dx.doi.org/ (Open Access)
-
A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumorsIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. 366PDOnline Full Text: dx.doi.org/
-
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib : Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)In: Annals of Surgical Oncology Vol. 23 (2016) Nr. 6, pp. 1924 - 1927Online Full Text: dx.doi.org/
-
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma : a randomised, open-label, multicentre, phase 3 trialIn: Lancet Vol. 387 (2016) Nr. 10028, pp. 1629 - 1637Online Full Text: dx.doi.org/
-
Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFRIn: Angewandte Chemie International Edition Vol. 55 (2016) Nr. 36, pp. 10909 - 10912Online Full Text: dx.doi.org/
-
Covalent-Allosteric Kinase InhibitorsIn: Angewandte Chemie International Edition Vol. 54 (2015) Nr. 35, pp. 10313 - 10316Online Full Text: dx.doi.org/
-
Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas : subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072In: Annals of Oncology Vol. 25 (2014) Nr. 3, pp. 719 - 724Online Full Text: dx.doi.org/
-
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patientsIn: Clinical Cancer Research Vol. 20 (2014) Nr. 22, pp. 5745 - 5755Online Full Text: dx.doi.org/
-
Targeting glucose metabolism by 2-deoxyglucose in gastrointestinal stromal tumorsIn: Cancer Research Vol. 74 (2014) Nr. 19 Suppl.,Online Full Text: dx.doi.org/
-
DOG1 Regulates Growth and IGFBP5 in Gastrointestinal Stromal TumorsIn: Cancer Research Vol. 73 (2013) Nr. 12, pp. 3661 - 3670Online Full Text: dx.doi.org/
-
Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenib vs placebo in TKI-refractory metastatic GISTIn: Cancer Research Vol. 73 (2013) Nr. Suppl. 8,Online Full Text: dx.doi.org/
-
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trialIn: The Lancet Vol. 381 (2013) Nr. 9863, pp. 295 - 302Online Full Text: dx.doi.org/
-
Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST) : The EORTC STBSG ExperienceIn: Annals of Surgical Oncology Vol. 20 (2013) Nr. 9, pp. 2937 - 2943Online Full Text: dx.doi.org/
-
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor : a randomized trialIn: JAMA: Journal of the American Medical Association Vol. 307 (2012) Nr. 12, pp. 1265 - 1272Online Full Text: dx.doi.org/
-
Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cellsIn: Cancer Research Vol. 70 (2010) Nr. 1, pp. 150 - 159Online Full Text: dx.doi.org/
-
Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-α and melphalan : Histologically characterized improved margins correlate with absence of recurrencesIn: Annals of Surgical Oncology Vol. 16 (2009) Nr. 3, pp. 676 - 686Online Full Text: dx.doi.org/
-
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsIn: Cancer Research Vol. 69 (2009) Nr. 17, pp. 6941 - 6950Online Full Text: dx.doi.org/ (Open Access)